NTC Industries manufactures and sells cigarettes and tobacco products under brands like Regent and No. 10, while also operating a real estate development and rental business through its subsidiaries.
The company possesses a narrow moat derived from a regulatory license to manufacture cigarettes in India, a sector with high entry barriers. However, the financial metrics contradict a strong moat, as average ROE of 8.5% is below the cost of capital, suggesting the license does not translate into significant economic rent.
Management has prioritized reinvesting profits into business expansion and real estate ventures rather than paying dividends. Recent actions include significant preferential allotments of warrants to the promoter group to fund long-term capital requirements.
The investment collapsed as the promoter group prioritized their own interests over minority shareholders through dilutive warrant allotments and opaque real estate ventures. The regulatory license, which appeared to be a moat, proved worthless as the company failed to earn its cost of capital, and the ongoing litigation regarding asset transfers to subsidiaries eventually stripped the firm of its core value. A revolving door of key executives and persistent disclosure failures masked a deteriorating core business until the lack of transparency and poor capital allocation led to a permanent loss of capital.
RichFakir rates NTC Industries Ltd's business quality as poor — 38/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, NTC Industries Ltd is trading about 18% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on NTC Industries Ltd is: Not rated. A poor business at a fair price — it does not make our shortlist right now.
RichFakir's educational estimate of NTC Industries Ltd's fair value is about ₹173 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →